-

Humana Specialty Pharmacy Expands Access to New Cancer Treatment Options

LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Specialty Pharmacy has announced two significant additions to its comprehensive, personalized and targeted oncology therapies.

Patients can now receive the following drugs, delivered to their front doors in a fast and meaningful way, while Humana Specialty Pharmacy supports them along their journey:

  • TAGRISSO® (osimertinib), a drug that helps certain patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) manage their disease.
  • LENVIMA® (lenvatinib), a drug that helps patients with different forms of cancer, including certain types of thyroid, liver and kidney cancers.

Patients who receive TAGRISSO and LENVIMA from Humana Specialty Pharmacy also benefit from its Oncology Center of Excellence where Humana Specialty Pharmacy patient advocates and specialty pharmacists are available to provide invaluable treatment guidance, including help with managing daily symptoms, assistance on how and when to take medications, and any other questions they may have with respect to staying on their therapy.

“We are honored to be able to dispense these therapies and offer differentiated service and experience to patients through our Oncology Center of Excellence,” said Natalie Bedford, SVP, Humana Specialty Pharmacy. “At Humana Specialty Pharmacy, we are committed to providing a holistic and personal health care experience for all of the patients we serve, to drive overall better health outcomes.”

Humana Specialty Pharmacy, a part of Humana Pharmacy, manages therapies for chronic and complex illnesses while providing patients with both clinical and educational services customized to their individual needs and treatment goals.

More information about Humana Specialty Pharmacy can be found here.

About Humana
Humana Inc. (NYSE: HUM) is committed to helping our millions of medical and specialty members achieve their best health. Our successful history in care delivery and health plan administration is helping us create a new kind of integrated care with the power to improve health and well-being and lower costs. Our efforts are leading to a better quality of life for people with Medicare, families, individuals, military service personnel, and communities at large.

To accomplish that, we support physicians and other health care professionals as they work to deliver the right care in the right place for their patients, our members. Our range of clinical capabilities, resources and tools – such as in-home care, behavioral health, pharmacy services, data analytics and wellness solutions – combine to produce a simplified experience that makes health care easier to navigate and more effective.

More information regarding Humana is available to investors via the Investor Relations page of the company’s web site at www.humana.com, including copies of:

  • Annual reports to stockholders
  • Securities and Exchange Commission filings
  • Most recent investor conference presentations
  • Quarterly earnings news releases and conference calls
  • Calendar of events
  • Corporate Governance information

Contacts

Lisa Dimond
Humana Corporate Communications
832-330-4702
ldimond@humana.com

Humana Inc.

NYSE:HUM

Release Summary
Humana Specialty Pharmacy expands access to new cancer treatment options.
Release Versions

Contacts

Lisa Dimond
Humana Corporate Communications
832-330-4702
ldimond@humana.com

More News From Humana Inc.

Humana Announces New Strategic Joint Venture with BlackRock to Manage CenterWell Senior Primary Care Clinics

LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) today announced it has entered into a new joint venture agreement with funds and accounts managed by HPS Investment Partners, a part of BlackRock (“BlackRock”), to manage and operate an existing network of nearly 150 CenterWell Senior Primary Care clinics that currently sit within joint ventures owned by funds affiliated with WCAS and CenterWell. The new joint venture, majority owned by BlackRock and minority owned by CenterWell, will rep...

Humana Announces Improved CMS Star Ratings with 95 Percent of Medicare Advantage Members in 4-Star or Above Plans for 2027

LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM), a leading consumer healthcare company focused on helping people achieve their best health, today announced improved Star Ratings for 2027, highlighted by 95% of its Medicare Advantage members being enrolled in plans rated 4.0 stars or above by the Centers for Medicare and Medicaid Services (CMS). Additionally, 42% of Humana Medicare Advantage members are enrolled in 4.5-star plans for 2027.“We’re extremely proud of these Star Ratings. Th...

Humana Generates Nearly $20 Billion in Economic Impact Across Kentucky, New Report Finds

LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) and the University of Louisville today announced the publication of a new economic impact report examining Humana’s contributions across the state. The analysis, authored by University of Louisville applied economist Thomas E. Lambert, PhD, found that Humana’s operations generated nearly $20 billion in economic activity across Kentucky in 2025, supporting jobs, businesses and communities throughout the Commonwealth. The report, The Econo...
Back to Newsroom